Status:

TERMINATED

The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer

Lead Sponsor:

National Cancer Institute, Naples

Conditions:

Advanced Non-Small Cell Lung Cancer

Eligibility:

All Genders

Up to 75 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to compare the overall survival of patients with advanced non small cell lung cancer treated with docetaxel as single therapy versus docetaxel in combination with either g...

Detailed Description

This study is for patients with previously diagnosed advanced non small cell lung cancer (NSCLC, stage IIIb or IV) who had progression of their disease during or after first-line therapy containing pl...

Eligibility Criteria

Inclusion

  • Written informed consent
  • Age \> 18
  • Histological diagnosis of non small-cell lung cancer (NSCLC)
  • Stage IIIb or Stage IV disease (in IIIb, previous treatment with chemotherapy + radiotherapy, or metastatic supraclavicular lymph nodes or pleural effusion)
  • Disease in progression
  • Previous chemotherapy with platinum-derivative (and with \> 21 days from last administration)

Exclusion

  • ECOG performance status \> 2
  • Age \> 75 years
  • History of malignant neoplasm within the previous 5 years (except for baso- or spino-cellular skin carcinoma and in-situ carcinoma of the uterine cervix, provided they are being adequately treated)
  • Previous treatment with docetaxel
  • Presence of symptomatic cerebral metastasis
  • Neutrophils \< 2.0 x 109/l, platelets \< 100,000/l, hemoglobin \> 10g/dl
  • Bilirubin \< 1.5 x the upper normal limit
  • SGOT , SGPT, or bilirubin \> 1.25 x the upper normal limits except in the presence of hepatic metastasis
  • Creatinine \>1.25 x the upper normal limit
  • Any concomitant pathology that would, in the Investigator's opinion, contraindicate the use of the drugs in the protocol
  • Inability to comply with follow up
  • Pregnant or nursing females

Key Trial Info

Start Date :

May 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2008

Estimated Enrollment :

84 Patients enrolled

Trial Details

Trial ID

NCT00345059

Start Date

May 1 2005

End Date

May 1 2008

Last Update

January 14 2016

Active Locations (24)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (24 locations)

1

Azienda Ospedaliera Giovanni Paolo II

Sciacca, AG, Italy

2

Azienda Ospedaliera S. Giuseppe Moscati, U.O. di Oncologia Medica

Monteforte Irpino, AV, Italy, 83024

3

Ospedale Fatebenefratelli, U.O. di Oncologia

Benevento, BN, Italy, 82100

4

Azienda Ospedaliera G. Rummo

Benevento, BN, Italy